Nov 6 (Reuters) - Bristol Myers Squibb (BMY.N) has acquired Orum Therapeutics’ experimental therapy to treat a type of blood cancer for a total value of up to $180 million, the privately held company said on Monday.
The therapy, ORM-6151, which helps degrade a specific protein hard to treat previously, has received the U.S. Food and Drug Administration’s (FDA) clearance for an early stage study.
The deal includes an upfront payment of $100 million and milestone payments, Orum said, without disclosing further details.

百时美施贵宝

路透 11 月 6 日电 - 私人持股的百时美施贵宝周一表示，该公司已收购 Orum Treateutics 治疗一种血癌的实验性疗法，总价值高达 1.8 亿美元。

百时美施贵宝以高达 1.8 亿美元收购 Orum 的血癌疗法